Premium
Survival benefit of neoadjuvant chemotherapy and surgery versus surgery first for resectable colorectal liver metastases: a cohort study
Author(s) -
Behrenbruch Corina,
Prabhakaran Sowmya,
Udayasiri Dilshan,
Hollande Frédéric,
Michael Michael,
Hayes Ian,
Heriot Alexander,
Knowles Brett,
Thomson Benjamin
Publication year - 2021
Publication title -
anz journal of surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.426
H-Index - 70
eISSN - 1445-2197
pISSN - 1445-1433
DOI - 10.1111/ans.16613
Subject(s) - medicine , hazard ratio , proportional hazards model , confidence interval , colorectal cancer , retrospective cohort study , oncology , cohort , chemotherapy , surgery , confounding , cancer
There is continued debate about the survival benefit of neoadjuvant chemotherapy in patients with resectable colorectal liver metastases (CRLM). In this retrospective cohort study, we compared the overall survival and progression‐free survival between patients who received neoadjuvant chemotherapy prior to CRLM resection with those who underwent CRLM upfront. A multivariable Cox proportional hazard regression analysis was performed to adjust for potential confounders.